This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DCA is currently undergoing the open label phase of a phase 3 controlled clinical trial on the GCRC as an investigational drug that has been designated by the Food and Drug Administration as an Orphan Product for congenital lactic acidosis-CLA, a collection of rare inborn errors of mitochondrial metabolism causing cellular energy failure and early death. DCA is postulated to benefit patients with this disease because it directly inhibits mitochondrial pyruvate dehydrogenase-PDH- kinase, thereby indirectly activating the PDH complex and facilitating both lactate removal and the efficient conversion of substrate fuel into energy. Recent advances in our understanding of the mechanisms of DCA biotransformation in vivo provide exciting new insight into the possible causes, treatment and prevention of the adverse effects of chronic DCA exposure in humans. These novel findings include: gaining insight into the mechanisms by which DCA is biotransformed in vivo and in vitro to glyoxylate; identifying DCA as an inhibitor of maleylacetoacetate isomerase-MAAI, a key enzyme in mammalian tyrosine metabolism; discovering that MAAI inhibition by DCA may cause accumulation of intermediates in the tyrosine catabolic pathway that may be responsible for the hepatotoxicity and neurotoxicity of DCA;and showing this inhibition may also be responsible for prolonging the elimination half life of subsequent doses of DCA.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000082-47
Application #
7950696
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2008-12-01
Project End
2009-07-31
Budget Start
2008-12-01
Budget End
2009-07-31
Support Year
47
Fiscal Year
2009
Total Cost
$18,198
Indirect Cost
Name
University of Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Mangal, Naveen; James, Margaret O; Stacpoole, Peter W et al. (2018) Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children. J Clin Pharmacol 58:212-220
Boissoneault, Jeff; Letzen, Janelle; Lai, Song et al. (2016) Abnormal resting state functional connectivity in patients with chronic fatigue syndrome: an arterial spin-labeling fMRI study. Magn Reson Imaging 34:603-8
Shumyak, Stepan; Yang, Li-Jun; Han, Shuhong et al. (2016) ""Lupoid hepatitis"" in SLE patients and mice with experimental lupus. Clin Immunol 172:65-71
Hendeles, Leslie; Khan, Yasmeen R; Shuster, Jonathan J et al. (2015) Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 114:58-62.e2
Price, Catherine C; Levy, Shellie-Anne; Tanner, Jared et al. (2015) Orthopedic Surgery and Post-Operative Cognitive Decline in Idiopathic Parkinson's Disease: Considerations from a Pilot Study. J Parkinsons Dis 5:893-905
Krueger, Charlene A; Cave, Emily C; Garvan, Cynthia (2015) Fetal response to live and recorded maternal speech. Biol Res Nurs 17:112-20
Jones, Jacob D; Marsiske, Michael; Okun, Michael S et al. (2015) Latent growth-curve analysis reveals that worsening Parkinson's disease quality of life is driven by depression. Neuropsychology 29:603-9
Morishita, Takashi; Foote, Kelly D; Archer, Derek B et al. (2015) Smile without euphoria induced by deep brain stimulation: a case report. Neurocase 21:674-8
Del-Aguila, J L; Cooper-DeHoff, R M; Chapman, A B et al. (2015) Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. Pharmacogenomics J 15:153-7
Chapman, Arlene B; Cotsonis, George; Parekh, Vishal et al. (2014) Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens 27:546-54

Showing the most recent 10 out of 266 publications